CA2035927A1 - Process for purifying lipocortins - Google Patents
Process for purifying lipocortinsInfo
- Publication number
- CA2035927A1 CA2035927A1 CA002035927A CA2035927A CA2035927A1 CA 2035927 A1 CA2035927 A1 CA 2035927A1 CA 002035927 A CA002035927 A CA 002035927A CA 2035927 A CA2035927 A CA 2035927A CA 2035927 A1 CA2035927 A1 CA 2035927A1
- Authority
- CA
- Canada
- Prior art keywords
- rpp4
- lipo
- cortin
- solution
- proteins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000000412 Annexin Human genes 0.000 title claims abstract description 31
- 108050008874 Annexin Proteins 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims abstract description 23
- 230000008569 process Effects 0.000 title claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 150000001450 anions Chemical class 0.000 claims abstract description 5
- 239000003599 detergent Substances 0.000 claims abstract description 5
- 239000002738 chelating agent Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 18
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 15
- 238000004587 chromatography analysis Methods 0.000 claims description 11
- 238000001179 sorption measurement Methods 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 10
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000005995 Aluminium silicate Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 235000012211 aluminium silicate Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000001506 calcium phosphate Substances 0.000 claims description 6
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 6
- 235000011010 calcium phosphates Nutrition 0.000 claims description 6
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 235000018102 proteins Nutrition 0.000 description 33
- 239000007983 Tris buffer Substances 0.000 description 17
- 229920000669 heparin Polymers 0.000 description 13
- 229960002897 heparin Drugs 0.000 description 13
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229960005069 calcium Drugs 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000003463 adsorbent Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 5
- 229960001714 calcium phosphate Drugs 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 108090000669 Annexin A4 Proteins 0.000 description 2
- 102100034612 Annexin A4 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- -1 dextran sulfate Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 101710158668 Placental protein Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000008217 Pregnancy Proteins Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091000387 actin binding proteins Proteins 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002506 anticoagulant protein Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 102000036203 calcium-dependent phospholipid binding proteins Human genes 0.000 description 1
- 108091011005 calcium-dependent phospholipid binding proteins Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4721—Lipocortins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Abstract of the disclosure:
A process for purifying lipocortins A process for purifying lipocortins, in particular the proteins rPP4, rPP4-X and rPP4-delta prepared by gene manipulation, by treatment of a solution of a lipocortin with an anion exchanger in the presence of a chelating agent and of a detergent is described.
A process for purifying lipocortins A process for purifying lipocortins, in particular the proteins rPP4, rPP4-X and rPP4-delta prepared by gene manipulation, by treatment of a solution of a lipocortin with an anion exchanger in the presence of a chelating agent and of a detergent is described.
Description
2n~27 BEHRINGWERRE ARTIENGESELLSC~AFT HOE 90/B 004 - Ma 777 Dr. Ha/Sd Description A process for purifying lipocortins The invention relates to a process for purifying lipo-cortins, especially the proteins rPP4, rPP4-X and rPP4-delta prepared by gene manipulation. These proteins have anticoagulant and antiinflammatory effects.
The natural protein PP4 is described in EP-A 0 123 307.
The preparation of PP4, of a protein PP4-X which also has anticoagulant activity, and of a deletion variant with increased activity (PP4-delta) by gene manipulation is described in DE-A 39 10 240.
These proteins can be regarded as belonging to a group of proteins which are called lipocortins (glucocorticoid-induced phospholipase-inhibiting proteins) or calpactins (calcium-dependent phospholipid- and actin-binding proteins).
The object of the invention is to provide a process for obtaining and purifying lipocortins, especially the proteins PP4, PP4-X and PP4-delta prepared by gene manipulation (rPP4, rPP4-X and rPP4-delta).
Although processes for purifying PP4 are known, they are unsatisfactory for obtaining lipocortins prepared by gene manipulation because the composition of the initial solution differs.
The invention relates to a process for purifying a lipocortin by treating a solution thereof with an anion exchanger, which comprises adding to this solution a chelating agent and a detergent and contacting this solution with the exchanger and separatin~ off the liquid.
It is then possible to wash the exchanger with a deter-gent-free buffer solution and elute the lipocortin.
However, the lipocortin is obtained from the liquid where appropriate.
The described process is particularly suitable for lipocortins prepared by gene manipulation. A lipocortin of this type is, in particular, rPP4, rPP4-X or rPP4-delta. If addition of a chelating agent to a lipocortin solution results in a precipitate, the latter is prefer-ably separated off before adding a detergent.
A lipocortin-containing solution is, in particular, an E.coli lysate as are produced in gene manipulation pro-cesses using E.coli. The chelating reagent is used in a concentration of 0.001-0.05 mol/l, preferably 0.002-0.02 mol/l. The pH is ad~usted to 6.5-9.5, preferably pH
6.8-7.5. Detergents which can be used are ionic or nonionic or zwitterionic, preferably derivatives of cholic acid and salts thereof and RTriton X-100 in a concentration of 0.1-2.0% (generally).
Ion exchangers which can be used are basic ion exchangers, preferably Q-, QAE- or DEAE-RSepharose, -cellulose, -RSephadex or -RFractogel (a copolymer of pentaerythritol, methacrylic acid derivatives and poly-ethylene glycol which carries amino groups and is cross-linked with divinylbenzene) or hydroxyapatite. It is possible to carry out adsorption from a buffer solution of 0.01-0.1 mol/l tris, HEPES or glycine at a pH of 6.5-9.5.
Whereas rPP4 and rPP4-delta are bound to the anion exchanger under the described conditions, rPP4-X is not 3 ~ ~
bound at pH 6.5-8Ø Xowever, enrichment of this protein is achieved because a large part of the contaminating proteins is adsorbed onto the exchanger.
It has also been found, surprisingly, that rPP4-X and rPP4-delta also, besides rPP4, bind to immobilized polysulfuric acid esters of saccharides or carrier-bound sulfated sugars, but only in the presence of calcium, at a conductivity of 0-10 mS and a pH of 6.5-9.5; the proteins can be eluted by increasing the ionic strength.
These proteins do not bind to these adsorbents in the absence of calcium or in the presence of chelating reagents.
rPP4, rPP4-X or rPP4-delta can be further purified by adsorption onto kaolin or RAerosil in the presence of calcium. Elution is effected by increasing the ionic strength and/or using chelating reagents.
It is also possible to use binding to calcium phosphate for further purification of these proteins. These pro-teins can be eluted by increasing the ionic strength or using chelating reagents such as EDTA or salts of citric acid or by a mixture containing these reagents.
The lipocortins can be subjected to affinity chromato-graphy for further purification. For this purpose, the lipocortin-containing solutions can be dialyzed, adsorbed in a buffer containing 0.01-0.05 mol/l, preferably 0.02 mol/l, tris-HCl, pH 8.5, after addition of calcium ions in a batch process onto carrier-bound heparin, the adsorbent can be washed, and the proteins can be eluted using a stepped gradient and subsequently dialyzed. The dialysates are mixed with 0.01-20 mmolJl, preferably 1 mmol/l, EDTA, preferably contacted once more with carrier-bound heparin, and the lipocortins dialyzed.
This affinity chromatography can generally ~e carried out on carrier-bound polysulfuric acid esters of saccharides ?f~?~27 or sulfated sugars, for example carrier-bound heparin, dextran sulfate, heparan sulfate, chondroitin sulfate, keratan sulfate or dermatan sulfate, preferably heparin-RSepharose or -RFractogel or dextran sulfate-R~epharose or -RFractogel, from a buffer solution which contains 0.01-O.1 mol/l tris, HEPES or glycine, at a pH of 6.5-9.5, preferably pH 6.8-8.5, which preferably contains 5 mmol/l calcium, and by elution of adsorbed proteins by increas-ing the ionic strength as for the ion exchanger chromato-graphy. In the absence of calcium or presence of chelat-ing reagents, rPP4, rPP4-X and rPP4-delta do not bind to these adsorbents.
Further purification can be carried out by adsorption onto RAerosil or kaolin, especially onto RAerosil 200 (from Serva) or kaolin (from Ser~a) and from E.coli fermentation media (see above) or from a buffer solution with a pH of 6.5-9.5 which contains 0.01-0.1 mol/l tris, HEPES or glycine and 1-20 mmol/l calcium. Adsorbed proteins can be eluted by increasing the ionic strength as for the ion exchanger chromatography and/or using chelating reagents, preferably 1-20 mmol/l EDTA or 0.01-0.2 mol/l of a salt of citric acid or a mixture.
In a preferred procedure, lipocortin-containing solutions from E.coli fermentation mixtures or buffer solutions composed of 0.01-0.1 mol/l tris/HCl, HEPES or glycine and a pH of 6.5-9.5 are mixed with calcium to a final concen-tration of 1-10 mmol/l, contacted with kaolin, RAerosil 200 or calcium phosphate while shaking, the liquids are separated off, the adsorbent is washed and adsorbed proteins are eluted using a chelating r~agent, preferably EDTA or salts of citric acid or a mixture. After dialysis of the eluates, further purification of the proteins can be continued by adsorption onto a heparin-resin as described above.
Adsorption and elution of the proteins on calcium phos-phate is carried out as described for adsorption onto RAerosil and kaolin, but the presence of calcium is not necessary for binding.
A particularly preferred procedure is the combination (EDTA/RTriton) DEAE exchanger, then heparin chromatography with Ca2t and then heparin chromatography with EDTA as described in Example 1.
All the process steps can be carried out at room tempera-ture. Exceptions are indicated.
The following abbreviations are used for the description:
RAerosil 200: silicon dioxide t DEAE: diethylaminoethyl EDTA: ethylenediaminetetraacetic acid HEPES: N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid Kaolin: hydrated aluminum silicate PAGE: polyacrylamide gel electrophoresis PP4: placental protein 4 Q: quaternary amino RRivanol: 6,9-diamino-2-ethoxyacridine lactate SDS: sodium dodecyl sulfate Tris: tris(hydroxymethyl)aminomethane VAC: vascular anticoagulant The in~ention is illustrated by the examples which follow:
~ample 1 a) Solubilization of phospholipid-associated proteins 1.0 1 of centrifuged E.coli lysates which contained 1.0 mg/ml rPP4 or rPP4-delta in 0.05 mol/l tris/HCl, pH
7.5, 5 mmol/l EDTA were mixed with RTriton X-100 to a final concentration of 1.0~, incubated at room tempera-ture while shaking for 10 min and then centrifuged.
- 6 ~ 3 2 7 b) Ion exchanger chromatography The supernatant after c~ntrifugation was contacted with 300 ml of DEAE-~Sepharose ("resin material~') equilibrated with 0.02 mol/l tris/HCl, pH 7.5 (column buffer 1), while stirring for one hour, the liquid was removed by filtra-tion, the adsorbent was washed with column buffer l, and the resin material was packed into a column. Adsorbed proteins were eluted with column buffer 1 which contained 0.25 mol/l NaCl.
c) Adsorption onto carrier-bound heparin (+calcium) After dialysis, the ion exchanger eluate (300 ml) was, if necessary, adjusted to a protein concentration of 0.2-3.0 mg/ml of rPP4 or rPP4-delta after addition of CaCl2 to a final concentration of 5 mmol/l, contacted with 70 ml of heparin-RFractogel equilibrated with 0.02 mol/l tris/HCl, pH 8.5, 5 mmol~l CaCl2 (column buffer 2), while stirring for one hour, the supernatant liquid was fil-tered off, the resin was washed with column buffer 2, and adsorbed proteins were eluted by increasing the ionic strength using a 0.3 molar NaCl buffer solution.
d) Heparin chromatography (+EDTA) After dialysis, the heparin eluate (100 ml) was mixed with EDTA to a final concentration of 1 mmol/l, contacted with 50 ml of heparin-resin, equilibrated with 0.02 M
tris/HCl, pH 8.5, 1 mM EDTA (column buffer 3) in a column, and the flow-through containing rPP4 or rPP4-delta was dialyzed against a solution of 0.02 M tris/HCl, pH 6.8-8.5, and then lyophilized. After the lyophilisates had been dissolved in appropriate volumes of distilled water or buffer solutions, the recovered biological activities were 95-100% of those of the materials before freeze-drying.
The purity o the rPP4-heparin flow-throughs (d) was - 7 - ~ 7 >95%. The yield was about 55% based on the starting materials and about 40% for rPP4-delta.
~xample 2 a) Solubilization of phospholipid-associated proteins 1.0 1 of centrifuged E.coli lysates in 0.02 M tris/HCl, pH 6.8, which contained 0.8 mg/l rPP4-X at a total protein concentration of about 20 mg~ml was mixed with Triton X-100 to a final concentration of 1.0~, incubated with shaking for 10 min and then centrifuged.
b) Ion exchanger chromatography The supernatant after centrifugation was contacted with 300 ml of DEAE-Sepharose, equilibrated with 0.02 M
tris/HCl, pH 6.8, with stirring, the liquid was removed by filtration, the adsorbent was washed and the resin material was packed into a column. Adsorbed proteins were eluted with a buffer solution which contained 1.5 M NaCl.
The solution containing rPP4-X which was filtered off after the incubation with the ion exchanger resin was adjusted to a pH of 8.5, mixed with 5 mmol/l CaCl2, incubated with carrier-bound heparin, the adsorbent was washed with a solution of 0.02 M tris/HCl, pH 8.5, adsorbed proteins were eluted, the eluate was dialyzed and, after addition of 1 mmol/l EDTA, again incubated with heparin-resin as described in Example 1, c. and d.
2~ It was surprisingly found that rPP4-X did not bind to the anion exchanger under these conditions. Nevertheless, a considerable purifying effect was achieved thereby because part of the E.coli proteins were adsorbed onto the resin. The yield after the heparin chromatographies was about 60% based on the starting material, i.e. about 480 mg of rPP4-X with a purity of >95~.
- 8 - ~ 7 Example 3 Adsorption onto kaolin, RAerosil 200 or calcium phosphate Centrifuged E.coli lysate solutions from 0.05 N tris~HCl, pH 7.5, which contained 1.0 mg/ml rPP4, rPP4-X or rPP4-delta, with a total protein content of about 20 mg/ml,were mixed with 5 mM CaCl2 and, in separate mixtures, incubated in each case with 25 mg of kaolin or RAerosil 200 per ml of protein solution while stirring for an hour, and the adsorbent was washed with a solution of 0.02 mol/l tris/HCl, pH 8Ø Adsorption onto calcium phosphate took place under the same conditions but the presence of calcium was unnecessary for binding. Adsorbed proteins were eluted with a solution of 0.02 M tris/HCl, pH 8.0, which contained 0.02 mol/l EDTA or a mixture of 0.01 M EDTA and 0.1 M sodium citrate.
After the eluates had been dialyzed against a buffer solution of 0.02 M tris/HCl, pH 8.5, the purification of the proteins was continued by adsorption onto carrier-bound heparin as described in Example 1, c. and d. The yields of the >95% pure proteins rPP4 and rPP4-X after the heparin chromatographies were between 50 and 60%
based on the starting materials.
The proteins rPP4 and rPP4-X purified as described in the Examples were tested for their physicochemical and biological properties. All their properties were identi-cal to those of the corresponding proteins isolated from placenta.
The natural protein PP4 is described in EP-A 0 123 307.
The preparation of PP4, of a protein PP4-X which also has anticoagulant activity, and of a deletion variant with increased activity (PP4-delta) by gene manipulation is described in DE-A 39 10 240.
These proteins can be regarded as belonging to a group of proteins which are called lipocortins (glucocorticoid-induced phospholipase-inhibiting proteins) or calpactins (calcium-dependent phospholipid- and actin-binding proteins).
The object of the invention is to provide a process for obtaining and purifying lipocortins, especially the proteins PP4, PP4-X and PP4-delta prepared by gene manipulation (rPP4, rPP4-X and rPP4-delta).
Although processes for purifying PP4 are known, they are unsatisfactory for obtaining lipocortins prepared by gene manipulation because the composition of the initial solution differs.
The invention relates to a process for purifying a lipocortin by treating a solution thereof with an anion exchanger, which comprises adding to this solution a chelating agent and a detergent and contacting this solution with the exchanger and separatin~ off the liquid.
It is then possible to wash the exchanger with a deter-gent-free buffer solution and elute the lipocortin.
However, the lipocortin is obtained from the liquid where appropriate.
The described process is particularly suitable for lipocortins prepared by gene manipulation. A lipocortin of this type is, in particular, rPP4, rPP4-X or rPP4-delta. If addition of a chelating agent to a lipocortin solution results in a precipitate, the latter is prefer-ably separated off before adding a detergent.
A lipocortin-containing solution is, in particular, an E.coli lysate as are produced in gene manipulation pro-cesses using E.coli. The chelating reagent is used in a concentration of 0.001-0.05 mol/l, preferably 0.002-0.02 mol/l. The pH is ad~usted to 6.5-9.5, preferably pH
6.8-7.5. Detergents which can be used are ionic or nonionic or zwitterionic, preferably derivatives of cholic acid and salts thereof and RTriton X-100 in a concentration of 0.1-2.0% (generally).
Ion exchangers which can be used are basic ion exchangers, preferably Q-, QAE- or DEAE-RSepharose, -cellulose, -RSephadex or -RFractogel (a copolymer of pentaerythritol, methacrylic acid derivatives and poly-ethylene glycol which carries amino groups and is cross-linked with divinylbenzene) or hydroxyapatite. It is possible to carry out adsorption from a buffer solution of 0.01-0.1 mol/l tris, HEPES or glycine at a pH of 6.5-9.5.
Whereas rPP4 and rPP4-delta are bound to the anion exchanger under the described conditions, rPP4-X is not 3 ~ ~
bound at pH 6.5-8Ø Xowever, enrichment of this protein is achieved because a large part of the contaminating proteins is adsorbed onto the exchanger.
It has also been found, surprisingly, that rPP4-X and rPP4-delta also, besides rPP4, bind to immobilized polysulfuric acid esters of saccharides or carrier-bound sulfated sugars, but only in the presence of calcium, at a conductivity of 0-10 mS and a pH of 6.5-9.5; the proteins can be eluted by increasing the ionic strength.
These proteins do not bind to these adsorbents in the absence of calcium or in the presence of chelating reagents.
rPP4, rPP4-X or rPP4-delta can be further purified by adsorption onto kaolin or RAerosil in the presence of calcium. Elution is effected by increasing the ionic strength and/or using chelating reagents.
It is also possible to use binding to calcium phosphate for further purification of these proteins. These pro-teins can be eluted by increasing the ionic strength or using chelating reagents such as EDTA or salts of citric acid or by a mixture containing these reagents.
The lipocortins can be subjected to affinity chromato-graphy for further purification. For this purpose, the lipocortin-containing solutions can be dialyzed, adsorbed in a buffer containing 0.01-0.05 mol/l, preferably 0.02 mol/l, tris-HCl, pH 8.5, after addition of calcium ions in a batch process onto carrier-bound heparin, the adsorbent can be washed, and the proteins can be eluted using a stepped gradient and subsequently dialyzed. The dialysates are mixed with 0.01-20 mmolJl, preferably 1 mmol/l, EDTA, preferably contacted once more with carrier-bound heparin, and the lipocortins dialyzed.
This affinity chromatography can generally ~e carried out on carrier-bound polysulfuric acid esters of saccharides ?f~?~27 or sulfated sugars, for example carrier-bound heparin, dextran sulfate, heparan sulfate, chondroitin sulfate, keratan sulfate or dermatan sulfate, preferably heparin-RSepharose or -RFractogel or dextran sulfate-R~epharose or -RFractogel, from a buffer solution which contains 0.01-O.1 mol/l tris, HEPES or glycine, at a pH of 6.5-9.5, preferably pH 6.8-8.5, which preferably contains 5 mmol/l calcium, and by elution of adsorbed proteins by increas-ing the ionic strength as for the ion exchanger chromato-graphy. In the absence of calcium or presence of chelat-ing reagents, rPP4, rPP4-X and rPP4-delta do not bind to these adsorbents.
Further purification can be carried out by adsorption onto RAerosil or kaolin, especially onto RAerosil 200 (from Serva) or kaolin (from Ser~a) and from E.coli fermentation media (see above) or from a buffer solution with a pH of 6.5-9.5 which contains 0.01-0.1 mol/l tris, HEPES or glycine and 1-20 mmol/l calcium. Adsorbed proteins can be eluted by increasing the ionic strength as for the ion exchanger chromatography and/or using chelating reagents, preferably 1-20 mmol/l EDTA or 0.01-0.2 mol/l of a salt of citric acid or a mixture.
In a preferred procedure, lipocortin-containing solutions from E.coli fermentation mixtures or buffer solutions composed of 0.01-0.1 mol/l tris/HCl, HEPES or glycine and a pH of 6.5-9.5 are mixed with calcium to a final concen-tration of 1-10 mmol/l, contacted with kaolin, RAerosil 200 or calcium phosphate while shaking, the liquids are separated off, the adsorbent is washed and adsorbed proteins are eluted using a chelating r~agent, preferably EDTA or salts of citric acid or a mixture. After dialysis of the eluates, further purification of the proteins can be continued by adsorption onto a heparin-resin as described above.
Adsorption and elution of the proteins on calcium phos-phate is carried out as described for adsorption onto RAerosil and kaolin, but the presence of calcium is not necessary for binding.
A particularly preferred procedure is the combination (EDTA/RTriton) DEAE exchanger, then heparin chromatography with Ca2t and then heparin chromatography with EDTA as described in Example 1.
All the process steps can be carried out at room tempera-ture. Exceptions are indicated.
The following abbreviations are used for the description:
RAerosil 200: silicon dioxide t DEAE: diethylaminoethyl EDTA: ethylenediaminetetraacetic acid HEPES: N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid Kaolin: hydrated aluminum silicate PAGE: polyacrylamide gel electrophoresis PP4: placental protein 4 Q: quaternary amino RRivanol: 6,9-diamino-2-ethoxyacridine lactate SDS: sodium dodecyl sulfate Tris: tris(hydroxymethyl)aminomethane VAC: vascular anticoagulant The in~ention is illustrated by the examples which follow:
~ample 1 a) Solubilization of phospholipid-associated proteins 1.0 1 of centrifuged E.coli lysates which contained 1.0 mg/ml rPP4 or rPP4-delta in 0.05 mol/l tris/HCl, pH
7.5, 5 mmol/l EDTA were mixed with RTriton X-100 to a final concentration of 1.0~, incubated at room tempera-ture while shaking for 10 min and then centrifuged.
- 6 ~ 3 2 7 b) Ion exchanger chromatography The supernatant after c~ntrifugation was contacted with 300 ml of DEAE-~Sepharose ("resin material~') equilibrated with 0.02 mol/l tris/HCl, pH 7.5 (column buffer 1), while stirring for one hour, the liquid was removed by filtra-tion, the adsorbent was washed with column buffer l, and the resin material was packed into a column. Adsorbed proteins were eluted with column buffer 1 which contained 0.25 mol/l NaCl.
c) Adsorption onto carrier-bound heparin (+calcium) After dialysis, the ion exchanger eluate (300 ml) was, if necessary, adjusted to a protein concentration of 0.2-3.0 mg/ml of rPP4 or rPP4-delta after addition of CaCl2 to a final concentration of 5 mmol/l, contacted with 70 ml of heparin-RFractogel equilibrated with 0.02 mol/l tris/HCl, pH 8.5, 5 mmol~l CaCl2 (column buffer 2), while stirring for one hour, the supernatant liquid was fil-tered off, the resin was washed with column buffer 2, and adsorbed proteins were eluted by increasing the ionic strength using a 0.3 molar NaCl buffer solution.
d) Heparin chromatography (+EDTA) After dialysis, the heparin eluate (100 ml) was mixed with EDTA to a final concentration of 1 mmol/l, contacted with 50 ml of heparin-resin, equilibrated with 0.02 M
tris/HCl, pH 8.5, 1 mM EDTA (column buffer 3) in a column, and the flow-through containing rPP4 or rPP4-delta was dialyzed against a solution of 0.02 M tris/HCl, pH 6.8-8.5, and then lyophilized. After the lyophilisates had been dissolved in appropriate volumes of distilled water or buffer solutions, the recovered biological activities were 95-100% of those of the materials before freeze-drying.
The purity o the rPP4-heparin flow-throughs (d) was - 7 - ~ 7 >95%. The yield was about 55% based on the starting materials and about 40% for rPP4-delta.
~xample 2 a) Solubilization of phospholipid-associated proteins 1.0 1 of centrifuged E.coli lysates in 0.02 M tris/HCl, pH 6.8, which contained 0.8 mg/l rPP4-X at a total protein concentration of about 20 mg~ml was mixed with Triton X-100 to a final concentration of 1.0~, incubated with shaking for 10 min and then centrifuged.
b) Ion exchanger chromatography The supernatant after centrifugation was contacted with 300 ml of DEAE-Sepharose, equilibrated with 0.02 M
tris/HCl, pH 6.8, with stirring, the liquid was removed by filtration, the adsorbent was washed and the resin material was packed into a column. Adsorbed proteins were eluted with a buffer solution which contained 1.5 M NaCl.
The solution containing rPP4-X which was filtered off after the incubation with the ion exchanger resin was adjusted to a pH of 8.5, mixed with 5 mmol/l CaCl2, incubated with carrier-bound heparin, the adsorbent was washed with a solution of 0.02 M tris/HCl, pH 8.5, adsorbed proteins were eluted, the eluate was dialyzed and, after addition of 1 mmol/l EDTA, again incubated with heparin-resin as described in Example 1, c. and d.
2~ It was surprisingly found that rPP4-X did not bind to the anion exchanger under these conditions. Nevertheless, a considerable purifying effect was achieved thereby because part of the E.coli proteins were adsorbed onto the resin. The yield after the heparin chromatographies was about 60% based on the starting material, i.e. about 480 mg of rPP4-X with a purity of >95~.
- 8 - ~ 7 Example 3 Adsorption onto kaolin, RAerosil 200 or calcium phosphate Centrifuged E.coli lysate solutions from 0.05 N tris~HCl, pH 7.5, which contained 1.0 mg/ml rPP4, rPP4-X or rPP4-delta, with a total protein content of about 20 mg/ml,were mixed with 5 mM CaCl2 and, in separate mixtures, incubated in each case with 25 mg of kaolin or RAerosil 200 per ml of protein solution while stirring for an hour, and the adsorbent was washed with a solution of 0.02 mol/l tris/HCl, pH 8Ø Adsorption onto calcium phosphate took place under the same conditions but the presence of calcium was unnecessary for binding. Adsorbed proteins were eluted with a solution of 0.02 M tris/HCl, pH 8.0, which contained 0.02 mol/l EDTA or a mixture of 0.01 M EDTA and 0.1 M sodium citrate.
After the eluates had been dialyzed against a buffer solution of 0.02 M tris/HCl, pH 8.5, the purification of the proteins was continued by adsorption onto carrier-bound heparin as described in Example 1, c. and d. The yields of the >95% pure proteins rPP4 and rPP4-X after the heparin chromatographies were between 50 and 60%
based on the starting materials.
The proteins rPP4 and rPP4-X purified as described in the Examples were tested for their physicochemical and biological properties. All their properties were identi-cal to those of the corresponding proteins isolated from placenta.
Claims (10)
1. A process for purifying a lipocortin by treating a solution thereof with an anion exchanger, which comprises adding to this solution a chelating agent and a detergent and contacting this solution with the exchanger and separating off the liquid.
2. The process as claimed in claim 1, wherein the exchanger is washed with a detergent-free buffer solution and the lipocortin is eluted.
3. The process as claimed in claim 1, wherein the lipo-cortin is obtained from the liquid.
4. The process as claimed in claim 1, wherein the lipo-cortin is a lipocortin prepared by gene manipulation.
5. The process as claimed in claim 1, wherein the lipo-cortin is rPP4, rPP4-X or rPP4-delta.
6. The process as claimed in claim 1, wherein the lipo-cortin-containing solution derives from an E.coli, yeast or animal cell culture.
7. The process as claimed in claim 1, wherein the lipo-cortin is further purified by chromatography on an immobilized polysulfuric acid ester of a saccharide or on a carrier-bound sulfated sugar.
8. The process as claimed in claim 1, wherein the lipo-cortin is further purified by chromatography on an immobilized polysulfuric acid ester of a saccharide or on a carrier-bound sulfated sugar in the presence of calcium ions and subsequently in the presence of EDTA.
9. The process as claimed in claim 1, wherein the lipo-cortin is further purified by adsorption onto kaolin, RAerosil or calcium phosphate.
10. The process as claimed in claim 1 and substantially as described herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4003773A DE4003773A1 (en) | 1990-02-08 | 1990-02-08 | METHOD FOR PURIFYING LIPOCORTINES |
DEP4003773.8 | 1990-02-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2035927A1 true CA2035927A1 (en) | 1991-08-09 |
Family
ID=6399691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002035927A Abandoned CA2035927A1 (en) | 1990-02-08 | 1991-02-07 | Process for purifying lipocortins |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0441274A3 (en) |
JP (1) | JPH0795894A (en) |
KR (1) | KR910015699A (en) |
AU (1) | AU7083191A (en) |
CA (1) | CA2035927A1 (en) |
DE (1) | DE4003773A1 (en) |
IE (1) | IE910410A1 (en) |
PT (1) | PT96693A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3910240A1 (en) * | 1989-03-30 | 1990-10-04 | Behringwerke Ag | PP4-DELTA, ITS PRODUCTION AND USE |
DE3911629A1 (en) * | 1989-04-10 | 1990-10-11 | Behringwerke Ag | METHOD FOR SEPARATING TOXINES FROM PROTEIN SOLUTIONS |
GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3315000A1 (en) * | 1983-04-26 | 1984-10-31 | Behringwerke Ag, 3550 Marburg | TISSUE PROTEIN PP (DOWN ARROW) 4 (DOWN ARROW), METHOD FOR ITS RECOVERY AND USE |
DE3643182A1 (en) * | 1986-12-18 | 1988-06-30 | Behringwerke Ag | MEDICINAL PRODUCTS CONTAINING THE TISSUE PROTEIN PP4, METHOD FOR THE PRODUCTION OF PP4 AND ITS PASTEURIZATION AND THE USE OF PP4 |
JP2660514B2 (en) * | 1987-02-20 | 1997-10-08 | 興和株式会社 | Polypeptide having anticoagulant action |
EP0286830A3 (en) * | 1987-03-13 | 1990-01-24 | BEHRINGWERKE Aktiengesellschaft | Process for the extraction of protein pp4 from tissues, and the use of citric acid therefor |
DE3724726A1 (en) * | 1987-07-25 | 1989-02-02 | Behringwerke Ag | METHOD FOR PURIFYING THE PLACENTARY TISSUE PROTEIN PP4 |
DE3911629A1 (en) * | 1989-04-10 | 1990-10-11 | Behringwerke Ag | METHOD FOR SEPARATING TOXINES FROM PROTEIN SOLUTIONS |
-
1990
- 1990-02-08 DE DE4003773A patent/DE4003773A1/en not_active Withdrawn
-
1991
- 1991-02-02 EP EP19910101409 patent/EP0441274A3/en not_active Withdrawn
- 1991-02-06 KR KR1019910001997A patent/KR910015699A/en not_active Withdrawn
- 1991-02-07 AU AU70831/91A patent/AU7083191A/en not_active Abandoned
- 1991-02-07 CA CA002035927A patent/CA2035927A1/en not_active Abandoned
- 1991-02-07 IE IE041091A patent/IE910410A1/en unknown
- 1991-02-07 PT PT96693A patent/PT96693A/en unknown
- 1991-02-07 JP JP3036501A patent/JPH0795894A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0441274A2 (en) | 1991-08-14 |
EP0441274A3 (en) | 1991-12-18 |
DE4003773A1 (en) | 1991-08-14 |
PT96693A (en) | 1991-10-31 |
KR910015699A (en) | 1991-09-30 |
JPH0795894A (en) | 1995-04-11 |
IE910410A1 (en) | 1991-08-14 |
AU7083191A (en) | 1991-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Owen et al. | Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His | |
US4629567A (en) | Alpha-1-antiprotease purification | |
EP0460882B1 (en) | Lipopeptide deacylase | |
AU691993B2 (en) | Process for purification of factor VIII | |
CA2058676C (en) | Process for isolating human albumin from supernatant iv, in particular iv-4, or from cohn's fraction v or from an analogous supernatant or fraction | |
US5097019A (en) | Pharmaceutical containing tissue protein pp4, a process for the preparation of pp4 and for the pasteurization thereof, and the use of pp4 | |
US4348316A (en) | New protein PP15, a process for its preparation and its use | |
CA2077888A1 (en) | Method for purifying factor viii and preparations obtained | |
US4990597A (en) | Process for the purification of placental tissue protein PP4 | |
CA2035927A1 (en) | Process for purifying lipocortins | |
US5136026A (en) | Process for removing toxins from protein solutions | |
Marcus et al. | Spinach chloroplast fructose-1, 6-bisphosphatase: identification of the subtilisin-sensitive region and of conserved histidines | |
US4780529A (en) | Isolation of an endotoxin inactivator from human plasma, and methods of use | |
AU641916B2 (en) | A process for removing toxins from protein solutions | |
US20090093038A1 (en) | Method for the production of pure virally inactivated butyrylcholinesterase | |
CA2171832C (en) | Alpha1-acid glycoprotein purification process and product | |
JPS62259596A (en) | Purification of hybrid protein | |
US20040106779A1 (en) | Modified factor IX preparation | |
EP0232384A1 (en) | Isolation of an endotoxin inactivator from human plasma | |
IE904254A1 (en) | Process for the purification of lipocortins | |
Murooka et al. | Affinity chromatography of Klebsiella arylsulfatase on tyrosyl-hexamethylenediamino-β-1, 3-glucan and immunoadsorbent | |
JP2722140B2 (en) | Method for producing human urinary trypsin inhibitor | |
US5760187A (en) | Purification process of a human growth hormone | |
JPH03176499A (en) | Method for purifying human urine trypsin inhibitor | |
JPH10265499A (en) | Purification of human growth hormone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |